# Gilead Sciences vs Novo Nordisk: stocks compared

URL: https://funkfolio.com/compare/gild-vs-nvo

> Gilead Sciences ($211.2B) and Novo Nordisk ($179.4B, P/E 10.5) compared: size, valuation, margins, debt, cash and price change.

---

## Gilead Sciences vs Novo Nordisk

Gilead Sciences (GILD), health care, and Novo Nordisk (NVO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Gilead Sciences is worth $211.2B on the stock market and Novo Nordisk $179.4B: Gilead Sciences is valued at 18% more. Gilead Sciences's operating margin in its latest fiscal year was 34.0% and Novo Nordisk's 41.3%. Over the past year Gilead Sciences's share price has moved +31.8% and Novo Nordisk's -12.5%.

### Key facts

- **Gilead Sciences market value:** $211.2B
- **Novo Nordisk market value:** $179.4B
- **Novo Nordisk P/E:** 10.5
- **Gilead Sciences revenue:** $29.4B FY to 2025-12-31
- **Novo Nordisk revenue:** $45.9B FY to 2025-12-31
- **Superinvestors holding both:** 2

Market values as of 18 Nov 2026, 04:26 UTC.

Gilead Sciences vs Novo Nordisk: every measure side by side

| Measure | Gilead Sciences | Novo Nordisk |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | Denmark |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $211.2B higher | $179.4B lower |
| Revenue | $29.4B lower | $45.9B higher |
| Earnings | $8.5B lower | $15.2B higher |
| Employees | 17,000 lower | 68,794 higher |
| Total assets | $59B lower | $80.6B higher |
| Valuation |  |  |
| P/E | — | 10.5 |
| P/S | 7.2 higher | 3.9 lower |
| P/B | 16.2 | — |
| Dividend yield | 1.94% | — |
| Profitability |  |  |
| Operating margin | 34.0% lower | 41.3% higher |
| Balance sheet |  |  |
| Net assets | $22.7B lower | $28.8B higher |
| Total liabilities | $36.4B lower | $51.8B higher |
| Total debt | $24.9B higher | $19.4B lower |
| Cash on hand | $7.6B higher | $3.9B lower |
| Price change |  |  |
| Today | +1.60% higher | -2.16% lower |
| 1 year | +31.8% higher | -12.5% lower |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Gilead Sciences 137.2, Novo Nordisk 84.0.

- Gilead Sciences (GILD)
- Novo Nordisk (NVO)

Gilead Sciences and Novo Nordisk share prices over one year, rebased to 100: Gilead Sciences ends at 137.2, Novo Nordisk at 84.0.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | GILD | NVO |
| --- | --- | --- |
| Nov 28, 2025 | 101.4 | 101.8 |
| Dec 31, 2025 | 98.9 | 105.0 |
| Jan 30, 2026 | 114.4 | 122.6 |
| Feb 27, 2026 | 120.0 | 77.3 |
| Mar 31, 2026 | 112.3 | 75.8 |
| Apr 30, 2026 | 105.4 | 87.1 |
| May 29, 2026 | 108.3 | 94.1 |
| Jun 30, 2026 | 101.8 | 98.9 |
| Jul 31, 2026 | 104.9 | 97.2 |
| Aug 31, 2026 | 117.9 | 93.5 |
| Sep 30, 2026 | 120.1 | 78.2 |
| Oct 30, 2026 | 137.5 | 82.5 |
| Nov 17, 2026 | 137.2 | 84.0 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (2)

- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 1.7% / 0.4%
- [Jim Simons (1938–2024)](https://funkfolio.com/gurus/jim-simons) 0.4% / 0.2%

#### Gilead Sciences only (8)

- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 0.9%
- [Josef Lakonishok](https://funkfolio.com/gurus/josef-lakonishok) 0.7%
- [John Rogers](https://funkfolio.com/gurus/john-rogers) 0.3%
- [Fred DiSanto](https://funkfolio.com/gurus/fred-disanto) 0.3%
- [Steve Cohen](https://funkfolio.com/gurus/steve-cohen) 0.3%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.3%
- [David Shaw (founder)](https://funkfolio.com/gurus/david-shaw) 0.2%
- [Ray Dalio (founder)](https://funkfolio.com/gurus/bridgewater) 0.2%

#### Novo Nordisk only (6)

- [Tom Gayner](https://funkfolio.com/gurus/tom-gayner) 0.8%
- [Lee Ainslie](https://funkfolio.com/gurus/lee-ainslie) 0.7%
- [Sarah Ketterer](https://funkfolio.com/gurus/sarah-ketterer) 0.6%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.4%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.2%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Gilead Sciences / Novo Nordisk). [Who owns GILD](https://funkfolio.com/stock/GILD/superinvestors) · [Who owns NVO](https://funkfolio.com/stock/NVO/superinvestors)

### More on Gilead Sciences

- [Gilead Sciences (GILD) stock page](https://funkfolio.com/stock/GILD)
- [Gilead Sciences market cap](https://funkfolio.com/stock/GILD/market-cap)
- [Gilead Sciences revenue](https://funkfolio.com/stock/GILD/revenue)
- [Gilead Sciences P/E ratio](https://funkfolio.com/stock/GILD/pe-ratio)
- [Gilead Sciences operating margin](https://funkfolio.com/stock/GILD/operating-margin)
- [Gilead Sciences total debt](https://funkfolio.com/stock/GILD/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Novo Nordisk

- [Novo Nordisk (NVO) stock page](https://funkfolio.com/stock/NVO)
- [Novo Nordisk market cap](https://funkfolio.com/stock/NVO/market-cap)
- [Novo Nordisk revenue](https://funkfolio.com/stock/NVO/revenue)
- [Novo Nordisk P/E ratio](https://funkfolio.com/stock/NVO/pe-ratio)
- [Novo Nordisk operating margin](https://funkfolio.com/stock/NVO/operating-margin)
- [Novo Nordisk total debt](https://funkfolio.com/stock/NVO/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Gilead Sciences against its closest peers

- [Gilead Sciences vs Amgen](https://funkfolio.com/compare/amgn-vs-gild)
- [Gilead Sciences vs Abbott Laboratories](https://funkfolio.com/compare/abt-vs-gild)
- [Gilead Sciences vs Thermo Fisher Scientific](https://funkfolio.com/compare/gild-vs-tmo)

#### Novo Nordisk against its closest peers

- [Novo Nordisk vs Abbott Laboratories](https://funkfolio.com/compare/abt-vs-nvo)
- [Novo Nordisk vs Pfizer](https://funkfolio.com/compare/nvo-vs-pfe)
- [Novo Nordisk vs Danaher](https://funkfolio.com/compare/dhr-vs-nvo)
- [Novo Nordisk vs Intuitive Surgical](https://funkfolio.com/compare/isrg-vs-nvo)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Gilead Sciences or Novo Nordisk?**

By market value, Gilead Sciences is the larger: $211.2B against $179.4B for Novo Nordisk. By revenue in its latest fiscal year, Novo Nordisk is the larger: $45.9B against $29.4B for Gilead Sciences.

**Which has the higher operating margin?**

Novo Nordisk: 41.3%, against 34.0% for Gilead Sciences. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has more debt?**

Gilead Sciences: $24.9B, against $19.4B for Novo Nordisk. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Gilead Sciences and Novo Nordisk?**

In their latest 13F filings, Dodge & Cox team and Jim Simons (1938–2024) hold both.

### Cite this page

Funkfolio, “Gilead Sciences vs Novo Nordisk”, data as of 18 November 2026. https://funkfolio.com/compare/gild-vs-nvo

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
